Leishmaniasis, Cutaneous: all 110 studies
Page 2 of 2. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.
- Surveillance for Leishmaniasis Skin Lesions in MaliCompletedNCT00344084
- Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous LeishmaniasisCompletedNCT00317980Phase 4
- Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous LeishmaniasisTerminatedNCT00317629Phase 3
- Imiquimod Plus Antimony Immunochemotherapy for Cutaneous LeishmaniasisCompletedNCT00257530Phase 3
- Miltefosine to Treat Cutaneous Leishmaniasis in BoliviaCompletedNCT00233545Phase 2
- Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania ParasiteCompletedNCT00121862Phase 2
- Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania ParasiteCompletedNCT00121849Phase 1
- Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous LeishmaniasisCompletedNCT00111553Phase 1
- Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in BrazilCompletedNCT00004755Phase 2
- Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as AdjuvantsCompletedNCT00001906Phase 1